Akebia Therapeutics, Inc. (NASDAQ:AKBA)‘s stock had its “buy” rating reissued by stock analysts at Aegis in a research note issued on Tuesday. They presently have a $21.00 price target on the biopharmaceutical company’s stock. Aegis’ target price indicates a potential upside of 109.79% from the stock’s current price.
Other analysts have also recently issued research reports about the stock. HC Wainwright boosted their target price on shares of Akebia Therapeutics from $17.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, December 27th. Zacks Investment Research upgraded shares of Akebia Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a research note on Friday, December 23rd. Needham & Company LLC set a $14.00 price target on shares of Akebia Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, December 20th. Finally, JMP Securities reiterated a “buy” rating on shares of Akebia Therapeutics in a research note on Thursday, November 10th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $15.75.
Shares of Akebia Therapeutics (NASDAQ:AKBA) opened at 10.01 on Tuesday. The company has a 50 day moving average of $10.00 and a 200-day moving average of $8.86. Akebia Therapeutics has a one year low of $7.00 and a one year high of $11.07. The firm’s market cap is $183.18 million.
“Akebia Therapeutics, Inc. (AKBA) Earns Buy Rating from Aegis” was originally posted by sleekmoney and is owned by of sleekmoney. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be read at http://sleekmoney.com/akebia-therapeutics-inc-akba-earns-buy-rating-from-aegis/1659978.html.
A number of institutional investors have recently bought and sold shares of AKBA. Dynamic Technology Lab Private Ltd bought a new position in Akebia Therapeutics during the fourth quarter valued at about $151,000. Trexquant Investment LP bought a new position in Akebia Therapeutics during the fourth quarter valued at about $344,000. Emerald Acquisition Ltd. bought a new position in Akebia Therapeutics during the second quarter valued at about $289,000. Dimensional Fund Advisors LP boosted its position in Akebia Therapeutics by 3.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 38,963 shares of the biopharmaceutical company’s stock valued at $406,000 after buying an additional 1,464 shares in the last quarter. Finally, Spark Investment Management LLC bought a new position in Akebia Therapeutics during the third quarter valued at about $469,000. Institutional investors and hedge funds own 49.50% of the company’s stock.
About Akebia Therapeutics
Akebia Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutics based on hypoxia inducible factor (HIF) biology, and the commercialization of these products for patients with serious medical needs. The Company’s segment is the business of developing and commercializing proprietary therapeutics based on HIF biology.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/akebia-therapeutics-inc-akba-earns-buy-rating-from-aegis/1659978.html
Receive News & Ratings for Akebia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.